Showing 1,281 - 1,300 results of 101,259 for search '(( 5 ((ng decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 5 step decrease ))', query time: 1.60s Refine Results
  1. 1281

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  2. 1282

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  3. 1283

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  4. 1284

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  5. 1285
  6. 1286

    Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

    Published 2013
    “…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”
  7. 1287
  8. 1288
  9. 1289
  10. 1290

    Decreased dermal and corneal stromal collagen in <i>Slc39a13</i>-KO mice. by Toshiyuki Fukada (156297)

    Published 2008
    “…Data represent mean±S.D. F. Collagen of corneal stroma is decreased in <i>Slc39a13</i>-KO mice. …”
  11. 1291
  12. 1292

    Blocking TNF or IL-6 decreases HIV-1 replication significantly in a dose dependent manner. by Shahin Ranjbar (66979)

    Published 2013
    “…Blocking TNF (at 2 ug/ml or 5 ug/ml) or IL-6 (5 ug/ml) significantly decreased virus replication (*, p<0.05) as compared to the same concentrations of an IgG<sub>1</sub> control antibody. …”
  13. 1293
  14. 1294

    Postnatal decrease in PV+ cortical interneurons in Fgfr1 mutant mice. by Karen Müller Smith (613941)

    Published 2014
    “…<p>PV and GFP immunostaining in 8 week old <i>Fgfr1<sup>f/f</sup>;Gad67-GFP+</i> control (<b>A</b>, n = 5) and <i>Fgfr1<sup>f/f</sup>;hGFAP-Cre;Gad67-GFP+</i> mutant mice (<b>B</b>, n = 9). …”
  15. 1295
  16. 1296
  17. 1297
  18. 1298
  19. 1299
  20. 1300